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Objectives We examined major issues associated with 
sharing of individual clinical trial data and developed a 
consensus document on providing access to individual 
participant data from clinical trials, using a broad 
interdisciplinary approach.
Design and methods This was a consensus-building 
process among the members of a multistakeholder task 
force, involving a wide range of experts (researchers, 
patient representatives, methodologists, information 
technology experts, and representatives from funders, 
infrastructures and standards development organisations). 
An independent facilitator supported the process using the 
nominal group technique. The consensus was reached in 
a series of three workshops held over 1 year, supported 
by exchange of documents and teleconferences within 
focused subgroups when needed. This work was set within 
the Horizon 2020-funded project CORBEL (Coordinated 
Research Infrastructures Building Enduring Life-science 
Services) and coordinated by the European Clinical 
Research Infrastructure Network. Thus, the focus was 
on non-commercial trials and the perspective mainly 
European.
Outcome We developed principles and practical 
recommendations on how to share data from clinical trials.
results The task force reached consensus on 10 
principles and 50 recommendations, representing the 
fundamental requirements of any framework used for 
the sharing of clinical trials data. The document covers 
the following main areas: making data sharing a reality 
(eg, cultural change, academic incentives, funding), 
consent for data sharing, protection of trial participants 
(eg, de-identification), data standards, rights, types 
and management of access (eg, data request and 
access models), data management and repositories, 
discoverability, and metadata.
Conclusions The adoption of the recommendations in 
this document would help to promote and support data 
sharing and reuse among researchers, adequately inform 
trial participants and protect their rights, and provide 
effective and efficient systems for preparing, storing and 
accessing data. The recommendations now need to be 
implemented and tested in practice. Further work needs to 
be done to integrate these proposals with those from other 
geographical areas and other academic domains.
IntrODuCtIOn
background 
In recent years, several major organisations 
have called for increased sharing of the 
data generated by publicly funded research, 
including the Organisation for Economic 
Co-operation and Development,2 the Euro-
pean Commission,3 the National Institutes of 
Health (NIH) in the USA4 and the G8 science 
ministers.5 This trend reflects the growing 
recognition that ‘Publicly funded research 
data are a public good, produced in the 
strengths and limitations of this study
 ► An effective and formal consensus-building 
process among a large group of very experienced 
researchers and others involved in clinical trials.
 ► A unique perspective: Europe-wide, non-commercial, 
with a focus on the particular needs of researchers.
 ► A large number of practical recommendations set 
against an overarching framework of principles.
 ► The recommendations now need to be implemented 
and tested in practice, and feasibility and usability 
should be explored.
 ► The exercise is largely based on experience and 
opinions, and members of the task force may be not 
fully representative of the research community.
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public interest, which should be made openly available 
with as few restrictions as possible in a timely and respon-
sible manner’.6 
Data from clinical research are not exempt from this 
call, even though concerns over participant privacy 
mean that such data often need to be specially prepared 
(eg, de-identified) before they can be shared. Given 
the key evidential role that clinical trials play in deter-
mining evidence-based medicine and evidence-based 
public health policies, sharing this type of data is seen 
as particularly important. Indeed, it has been argued 
that clinical trial data should be shared and treated as 
a public good whoever generates it, that is, whether 
they are created by publicly funded or commercial 
research.7
Sharing data from clinical research can be justified 
on scientific, economic and ethical grounds.8 Scien-
tifically, sharing makes it possible to compare or 
combine the data from different studies, and to more 
easily aggregate it for meta-analysis. It allows conclu-
sions to be re-examined and verified or, occasionally, 
corrected, and it can allow new hypotheses to be tested. 
Sharing can therefore increase data validity, but it also 
squeezes more value from the original research invest-
ment, as well as helps to avoid unnecessary repetition 
of studies. The economic advantages of data reuse are 
one reason why governmental and intergovernmental 
agencies, as well as major research funders (eg, the 
Gates Foundation9 and the Wellcome Trust10), support 
data sharing.
Ethically, data sharing provides a better way to honour 
the generosity of clinical trial participants, because it 
increases the utility of the data they provide and thus the 
value of their contribution. It is also argued that, if access 
to health and healthcare is a basic human right, access to 
data that can improve health is similarly a fundamental 
right,11 and those involved in research, and its governance 
and funding, have an obligation to their fellow citizens to 
respect and promote that right.12
The rapid acceptance of the idea of sharing clinical 
trial data was summarised in 2016 by Vickers,13 who was 
able to claim a ‘tectonic shift in attitudes’ over 10 years. 
Turning the idea of data sharing into a reality, so that it 
becomes ‘an unquestioned norm’ (to borrow Vickers’ 
phrase), certainly requires a change in attitudes, but 
there also needs to be an appropriate policy environ-
ment, adequate resourcing, clarity about the roles and 
responsibilities of different stakeholders, specific objec-
tives and indicators to measure progress, and an available 
digital infrastructure.
Origin of this document
The document has been prepared in the context of 
a specific working task of the European Union (EU) 
CORBEL (Coordinated Research Infrastructures 
Building Enduring Life-science Services) project (www. 
corbel- project. eu). CORBEL is designed to establish a 
collaborative and sustained framework of shared services 
across 11 participating European, European Strategy 
Forum on Research Infrastructures (ESFRI) biological 
and medical research infrastructures, to better support 
biomedical research in Europe and accelerate its transla-
tion into medical care.
One of the objectives of this working task is to develop 
procedures to provide the scientific community with 
access, on request, to the individual participant data 
(IPD) from previous clinical trials for reanalyses, 
secondary analyses and meta-analyses. This activity is 
led by the European Clinical Research Infrastructure 
Network (ECRIN-ERIC), an ESFRI research infrastruc-
ture that provides guidance, consulting and opera-
tions management for multinational clinical trials on 
a not-for-profit basis (www. ecrin. org). ECRIN already 
requests that the investigators it supports commit to 
make anonymised IPD data sets available to the scien-
tific community on request.
To be clear, throughout this document we use IPD 
to refer to all of the participant data available from a 
trial, and not just the data supporting the conclusions 
of a specific published paper. Such data will therefore 
normally be the data sets used for the various analyses, 
after appropriate de-identification and pseudonymisation 
or anonymisation measures have been applied. The goal 
is to develop a framework in which, ultimately, all of the 
participant-level data from any trial become available to 
those who can demonstrate they can make appropriate 
use of them.
Various other organisations have also addressed this 
task in recent years and developed generic principles 
as well as practical recommendations for implemen-
tation of data sharing. Usually, these documents are 
embedded in a geographical/national context (eg, the 
Institute of Medicine report in the USA,14 the Nordic 
Trial Alliance Working Group on Transparency and 
Registration for the Nordic countries,15 the good prac-
tice principles for sharing IPD from publicly funded 
trials by Medical Research Council (UK) (MRC), UK 
Clinical Research Consortium (UKCRC), Cancer 
Research UK (CRUK) and Wellcome in the UK,16 17 or 
the guide to publishing and sharing sensitive data for 
Australia18).
Other groups have examined clinical research data 
sharing within a much wider context, such as the 
principles of data management and sharing within 
European research infrastructures developed by 
BioMed Bridges.19 Conversely, other initiatives have 
been centred on a specific stakeholder group, such 
as the pharmaceutical industry (eg, the principles 
for responsible clinical trial data sharing produced 
by Pharmaceutical Research and Manufacturers of 
America (PHRMA) and European Federation of Phar-
maceutical Industries and Associations (EFPIA)20), or 
on specific subsets of clinical trial data (eg, the 2016 
International Committee of Medical Journal Editors 
(ICMJE) proposal was focused on the data underlying 
the results presented in an individual journal article21).
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These and other documents were taken into consider-
ation in our consensus exercise and, as a consequence, in 
this report. Nevertheless, we believe that in this report we 
have been able to bring a broader international perspec-
tive on data sharing in clinical trials, reflecting the profes-
sional and geographical diversity of our expert group. We 
have also tried to examine all stages of the data sharing 
‘life cycle’, including the following:
 ► Supporting trialists, for example, in planning for data 
sharing and in preparing data.
 ► Suggesting the best policies and practice for data and 
metadata storage.
 ► Promoting data discovery and discussing data access 
mechanisms and agreements.
The intention was to examine all the major issues associ-
ated with sharing IPD and trial documents, using a broad, 
multidisciplinary approach. Inevitably, however, certain 
perspectives have been emphasised, as described below.
the perspectives of this document
Trials or studies?
The remit of the task group was to look at data sharing 
from clinical trials, rather than clinical studies in 
general (the latter term including trials and non-inter-
ventional studies, both prospective and retrospective, 
including epidemiological and registry studies—see 
the glossary for formal definitions in online supple-
mentary 2). Although we have largely kept to that 
restriction, it should be acknowledged that many, 
probably most, of the principles and recommenda-
tions have relevance to clinical studies in general. That 
is sometimes reflected in the text, when ‘study’ is used 
rather than ‘trial’, but it is stressed that the formal 
scope of this document remains clinical trials.
Non-commercial trials
The emphasis of the project was on data sharing 
from non-commercial trials, partly because most of 
the expert group members have a background in 
non-commercial research. In addition, many of the 
existing non-commercial IPD sharing initiatives were 
perceived as having a limited scope, for example 
involving only specific collaborative trial groups or 
disease-specific activities. The task force was therefore 
keen to develop more generally applicable policies and 
guidance. Solutions developed in collaboration with 
the pharmaceutical companies (eg, Yale University 
Open Data Access (YODA)22 and Clinical Study Data 
Request (CSDR23)) may be applicable to the academic 
world, but so far this has not been tested. CORBEL 
wants to develop procedures and tools for the whole 
scientific community, while remaining complemen-
tary to existing initiatives. We believe that most if not 
all of the recommendations presented here are also 
applicable to IPD generated in the commercial sector. 
It should be noted that non-commercial clinical trials 
make up approximately 40% of the trials conducted 
in Europe.24 25
A European origin
The CORBEL project is funded by the EU and has 
a clear European perspective. Although several 
members of our working group represent institu-
tions from non-European countries (USA, Canada, 
Australia, observers from Japan) and we feel strongly 
that most of the recommendations have global scope, 
it is true that our discussions often referenced a Euro-
pean context, for instance when discussing personal 
data protection legislation. As many current initiatives 
about data sharing have a US base (eg, the Institute 
of Medicine,16 the Multi-regional Clinical Trial Centre 
(Harvard University) (MRCT) Center Vivli project,26 
and most of the ICMJE members), it could be argued 
that a European perspective is required, especially 
given the potential differences in legal frameworks 
as they relate to data sharing. It is also timely, given 
that the European Commission is pushing strongly 
for open access to scientific information, including 
supporting the development of a new European Open 
Science Cloud (EOSC) with major investment from 
the European Horizon 2020 research programme.27 
It is expected that sensitive data from clinical trials 
will constitute a major use case within this initiative. If 
successfully implemented, the EOSC could therefore 
provide a suitable infrastructure to host and share 
clinical trial data and documents.
The perspective of the researcher
The emphasis throughout has been on the perspective of 
clinical researchers, considered both as data generators 
and as data requesters/(re)users.
To be clear, by ‘data generators’ we mean the trialists 
and other study personnel that conceive of the study, and 
then plan, manage, monitor, analyse and publish it. This 
requires a complex set of intellectual and organisational 
skills, and we do not wish to suggest that a trial can be 
reduced to mere ‘data generation’, or that the term ‘data 
generators’ is used in any way in a derogatory sense. It is 
simply that, in this context, the term usefully emphasises 
the role of the trial as the data generation phase, and the 
role of the trialists as the designers and initial creators of 
the data set.
Other actors (funders, publishers, infrastructure 
providers) are all of course vitally important, but the 
main target group for this document are researchers 
themselves. We hope that this document will raise aware-
ness of IPD sharing among data generators and also show 
how, with suitable policies and tools, concerns about data 
sharing can be reduced.
Because publications and citations are of utmost 
importance in the academic world, the project also 
aims to promote data as a legitimate, citable product 
of research, and to ensure that making data available 
for sharing is recognised and rewarded. We have also 
tried to examine the needs of those searching for 
data and trial documents, emphasising the impor-
tance of discoverability and the need for transparent 
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but relatively simple mechanisms for requesting and 
gaining access.
The aim of this document is to help turn the sharing 
of data from clinical research, in particular from clin-
ical trials, from an aspiration to accepted practice. It 
does so by first proposing a set of overarching princi-
ples that we think should guide the practice of data 
sharing, and then examining the policy and practical 
issues associated with each and making a series of 
recommendations.
MethODs
This consensus exercise was carried out in a series of 
three workshops held over 12 months (March and 
October 2016, March 2017), supported by exchange 
of documents and teleconferences within focused 
subgroups when needed. Successive drafts of the 
report were circulated before each workshop, with 
final versions being circulated for comments, sugges-
tions and agreement after the third workshop. The 
applied methodology was based on the nominal group 
technique to ensure that all participants had a chance 
to formulate and contribute their opinions and to vote 
on the proposals.
The nominal group process28 29 is a strict, formal proce-
dure to facilitate innovation and creativity while still 
achieving consensus. It consists of the following steps:
1. Proposal of a text by a core group.
2. Comment from each group member.
3. Collection of comments by the moderator.
4. Collapsing of similar comments.
5. Prioritisation of discussion points.
6. Discussion of all comments.
7. Voting on each discussion point.
8. Rewriting of text by core group according to voting 
results.
9. Revision of new text by starting again at step (1) until 
consensus is reached.
The iteration process of step (9) was implemented by 
starting with a new revised text version at each workshop.
ECRIN established a core group responsible for the 
management of the consensus exercise and prepara-
tion of the consensus document. The group included 
experts in multinational clinical trials, trial method-
ology and transparency, trial management services, 
information technology (IT) tools, and legal issues. 
The core group’s responsibilities were to establish 
the multistakeholder task force, draft intermediate 
versions of this report, organise and manage the 
consensus workshops, coordinate the subgroups, and 
release the final version of the report.
Given the complexity of the issues around sharing and 
reusing data from clinical trials, any attempt to develop 
principles and procedures requires the involvement of 
a wide range of stakeholders to represent the different 
groups generating, managing and using IPD. It was also 
important to ensure that a range of scientific, technical and 
legal expertise was present, and that different geograph-
ical regions were represented in the discussion. A multis-
takeholder task force was therefore assembled including 
researchers, patient representatives, methodologists, 
information technology (IT) experts, and representatives 
from funders, infrastructures and standards development 
organisations, as well as the core group members, to 
evolve the consensus reported in this document.
Consensus building among the task force was carried 
out with the support of an independent facilitator, who 
cochaired the meetings and provided guidance on 
the consensus process and how to handle and report 
written feedback on the intermediate versions of the 
report. Online supplementary appendix 1 lists the full 
membership of the core group and multistakeholder 
task force.
During the first workshop, the task force agreed on 
the establishment of two subgroups to provide insights 
to the consensus exercise. The first subgroup worked 
on terminology, to clarify the main terms used in the 
project based on legal definitions, regulations and 
standards. The output of this subgroup is the glos-
sary of standardised terms and definitions reported 
in online supplementary appendix 2. The second 
subgroup worked on an environmental scan of the 
existing data sharing repositories and other initiatives 
relevant for sharing of IPD, to describe current provi-
sion and highlight possible missing features or func-
tions. The output of this subgroup will be reported in 
a separate publication.
results
Ten principles emerged from the consensus process, 
representing what the task force saw as the fundamental 
requirements for any framework for the sharing and 
reuse of clinical trials data. They are listed in box.
The task force also agreed 50 more detailed recommen-
dations, grouped around seven major topics, each asso-
ciated with one or more principles, as shown in figure 1.
These seven topics have been used to structure the 
lists of recommendations that follow. Each section 
also includes explanatory text for both principles and 
recommendations.
MAkIng DAtA shArIng A reAlIty
P1: the provision of IPD should be promoted, incentivised and 
resourced so that it becomes the norm in clinical research. 
Plans for data sharing should be described prospectively, and 
be part of study development from the earliest stages.
There is now widespread acceptance of the need for 
greater sharing of IPD, but much of the pressure for 
this has been ‘top-down’—it has come from funding 
organisations, professional bodies and journal editors 
(although some ‘bottom-up’ sharing activity also 
exists, eg, within collaborative research groups). Some 
researchers retain misgivings, for instance about the 
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resources required to support data preparation, or 
potential misinterpretation of their data, or a possible 
reduction in the number of papers they will be able 
to generate from the data themselves. These fears 
need to be recognised and mitigated by appropriate 
resourcing, policies and systems, including changes to 
the way research activity is recognised and rewarded. 
Such developments are necessary if making IPD and 
related study material available is ever to be seen as a 
normal, integral part of clinical research, accepted as 
such by the researchers themselves.
To help make that happen, researchers will need 
support, to ensure that data sharing is considered 
from the very beginning of study planning. Trying to 
organise safe and effective data sharing retrospectively, 
especially if appropriate consent and resourcing have 
not been obtained, will often be difficult, complex 
and expensive, and many non-commercial researchers 
would have great difficulty in justifying the additional 
input required. Making provision for future data 
sharing a standard component of study design is there-
fore essential.
1. All stakeholders involved in clinical research (eg, funders, 
patients’ groups, researchers, academia, professional groups, 
industry, editors, and regulatory and ethics authorities) 
should support sharing of IPD and study documents as a 
normal part of good practice.
Most of the major stakeholders in clinical research 
do recognise the importance of sharing IPD and trial 
documents, and many have made public statements 
to that effect. But these changes in attitude have to 
be turned into practical measures of support. No sin-
gle group can be held responsible as the main drivers 
of data sharing, and responsibility (and resourcing) 
needs to be shared—each stakeholder group will 
therefore have to evolve their own role within this de-
veloping field.
For example, actions taken by the European Medi-
cines Agency in Europe,30 by the US Congress with 
the 21st Century Cures Act in the USA31 and by the 
WHO in the context of public health emergencies32 
represent policy changes with respect to data sharing 
at national and international levels, but the full im-
plications of such changes will often need to be clar-
ified. Public funding agencies (eg, NIH in the USA) 
and funding charities (eg, Wellcome Trust, Bill and 
Melinda Gates Foundation) increasingly require that 
the studies they fund include data management and 
sharing strategies, but the practical limits to the finan-
cial support for data sharing from funders need to be 
explored. Biomedical journals, as exemplified by the 
ICMJE, are developing data sharing policies that will 
box Principles of data sharing in clinical trials  
(P, principle)
 ► P1: The provision of individual participant data should be promoted, 
incentivised and resourced so that it becomes the norm in clinical 
research. Plans for data sharing should be described prospectively, 
and be part of study development from the earliest stages.
 ► P2: Individual participant data sharing should be based on explicit 
broad consent by trial participants (or if applicable by their legal 
representatives) to the sharing and reuse of their data for scientific 
purposes.
 ► P3: Individual  participant data made available for sharing should 
be prepared for that purpose, with de-identification of data sets to 
minimise the risk of reidentification. The de-identification steps that 
are applied should be recorded.
 ► P4: To promote interoperability and retain meaning within 
interpretation and analysis, shared data should, as far as possible, 
be structured, described and formatted using widely recognised 
data and metadata standards.
 ► P5: Access to individual participant data and trial documents should 
be as open as possible and as closed as necessary, to protect 
participant privacy and reduce the risk of data misuse.
 ► P6: In the context of managed access, any citizen or group that has 
both a reasonable scientific question and the expertise to answer that 
question should be able to request access to individual participant 
data and trial documents.
 ► P7: The processing of data access requests should be explicit, 
reproducible and transparent, but, so far as possible, should 
minimise the additional bureaucratic burden on all concerned.
 ► P8: Besides the individual participant data sets, other clinical trial 
data objects should be made available for sharing (eg, protocols, 
clinical study reports, statistical analysis plans, blank consent 
forms) to allow a full understanding of any data set.
 ► P9: Data and trial documents made available for sharing should be 
transferred to a suitable data repository to help ensure that the data 
objects are properly prepared, are available in the longer term, are 
stored securely and are subject to rigorous governance.
 ► P10: Any data set or document made available for sharing should 
be associated with concise, publicly available and consistently 
structured discovery metadata, describing not just the data object 
itself but also how it can be accessed. This is to maximise its 
discoverability by both humans and machines.
Figure 1 Major aspects of sharing and reuse of data from 
clinical trials. P, principle.
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oblige authors to make the curated data and metada-
ta supporting their findings available,14 although the 
timing of such availability is the topic of debate. Inter-
national organisations that consider ethics in clinical 
research, for example the World Medical Association, 
have also issued statements about data reuse,33 and 
stakeholders will need to develop a consistent inter-
pretation of such principles.
The promotion of a culture of data sharing and reuse 
will therefore require an ongoing dialogue between 
all parties, parallel to the efforts aiming to encourage 
and monitor data sharing. Short-term projects such 
as CORBEL can play an important role in stimulating 
that dialogue, but more permanent infrastructure 
organisations, such as ECRIN, Biobanking and Bio-
Molecular Resources Research Infrastructure (BBM-
RI) and European Institute for Innovation through 
Health Data (i~HD), are likely to have a key role in 
orchestrating such discussions in the longer term.
2. Any data sharing model should be based on the concept of 
data ‘stewardship’ rather than data ‘ownership’.
The data generated in the context of clinical research 
activities should be seen as a public good—that is, one 
that is common to humanity as a whole. We believe 
that is the only way to properly recognise the value of 
the data and the generosity of the study participants 
who provided them. Although the researchers who 
generate the data may have the greatest stake in their 
use, they should not perceive it as their ‘private prop-
erty’. In fact (and despite the various practical issues 
that we discuss throughout this document) they have 
a responsibility to ensure the data are discoverable by 
others and accompanied by sufficient metadata for 
them to be found easily, understood in context and 
used appropriately. Commonly the term ‘stewardship 
of research data’ is used to summarise this approach, 
which includes providing useful accessibility, annota-
tion, curation and preservation of the data.34
We recognise that there are not, currently, formal 
definitions of ‘stewardship’ and ‘ownership’ of data 
that are universally accepted. There are specific uses 
of both terms, linked to debates about (for instance) 
contracts, copyright and intellectual property rights, 
but within the consensus conferences we wanted to 
keep clear of these more legal and technical issues. 
We wished to stress instead that the concept of stew-
ardship—as described above—should be the default 
assumption for IPD sharing, to be used when develop-
ing a policy framework and by individual researchers 
when considering their own data sharing strategies.
3. Academic and societal rewards for data sharing should be 
implemented so that making data available for data shar-
ing is seen by researchers as an opportunity. Such incentives 
might include recognition in the assessment of academic ca-
reers or grant proposals.
For researchers, planning, performing and analysing 
a clinical trial is a difficult, resource-intensive and 
lengthy exercise. In the academic world, reputation 
and career are mainly based on scientific presenta-
tions and publication of research results. Data shar-
ing may be highly desirable from a societal or ethi-
cal viewpoint but, up to now, the academic benefit 
for the data generators has been limited, although 
some analyses have reported that the citation rate of a 
publication is higher when its data are made publicly 
available.35
To help convince data generators to share their data, 
stronger incentives are necessary. The reuse of data 
sets generated by researchers should be valued in the 
assessment of academic careers, including for pro-
motion, as part of a more comprehensive evaluation 
of the professional work of trialists. Shared data sets 
therefore need to become an acceptable academic 
coinage. Agreed mechanisms for including data shar-
ing in academic career assessment are not yet avail-
able, but a variety of detailed proposals have been 
made and will need to be tested in practice.36 37 The 
evaluation of funding applications should also take 
into account the applicant’s past record of making 
IPD data available for sharing, and the subsequent 
level of reuse of that data.
4. Clinical trial data sets should be considered legitimate, cit-
able products of research. To support citability they must each 
have a persistent and globally recognised identifier.
Persistent identifiers, such as the already widely used 
digital object identifier (DOI), should be applied 
to data sets to improve discoverability and to allow 
correct citation. The issue of data citation is current-
ly being intensively addressed,37–40 and it is hoped 
that widely accepted procedures for data citation 
will evolve in the very near future. For example, the 
Force11 Data Citation Synthesis Group has published 
a Joint Declaration of Data Citation Principles,41 
which has been endorsed by 94 repositories, publish-
ers and scholarly organisations, including DataCite, 
Committee on Data (of the International Council 
for Science) (CODATA) and the Nature Publishing 
Group.42 In addition, several organisations and pub-
lishers have introduced metrical instruments for data 
citation.43 44 Identifier, citation and citation metric 
schemes are an essential prerequisite for the broad 
acceptance and implementation of data sharing.
A potential problem in assigning identifiers is that 
different versions of data sets and documents may 
be available. For instance, trial protocols are often 
amended and consequently assigned different ver-
sion numbers, or a long-running study might gener-
ate additional follow-up data. Even data generated 
at the same time may exist in different forms, for in-
stance trial analysis data versus the same, partly un-
coded, data set, as originally collected on (e)CRFs. 
Versioning is a problem common to many types of 
data storage, and various technical approaches have 
been proposed—the simplest being distinct DOIs for 
different versions, but with the linkage between ver-
sions retained explicitly in other metadata elements. 
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The key point we make here is that a generally ap-
plied versioning scheme would be a necessary part of 
any overall approach to assigning identifiers to trial 
data sets and documents.
5. Stakeholders involved in clinical research need to develop 
fair and sustainable financial models for data sharing, to 
ensure the long-term resourcing of data preparation and stor-
age as well as the request and sharing process.
The costs of preparing data for secondary use, its sub-
sequent maintenance in repositories and the request 
and access processes all need to be adequately fund-
ed. Inclusion of initial preparation costs in funding 
applications is probably the most obvious option, but 
different mechanisms for sustainable funding of data 
sharing need to be explored. We believe that charg-
ing fees for access to data should be avoided wherever 
possible, as it could discourage applications for ac-
cess, especially from academic researchers and from 
low-income or middle-income countries. We accept, 
however, that there may be situations (eg, for legacy 
trials) where some of the costs of preparing data for 
sharing may need to be met by the secondary users, 
or it will be difficult to make the data available. Irre-
spective of the business model adopted, the final goal 
must be to encourage data sharing and reuse.
Long-term storage and access costs are not easily pre-
dictable and thus not easily linked to initial funding.
Possible sources of support include core/structur-
al funding, hosting organisations or private contract-
ing, data deposition fees, access charges, or research 
and development (R&D) project funding.45 The dis-
cussion on sustainable business models for data infra-
structures is ongoing, and it is difficult to identify a 
preferred model. A particular problem is that while 
many established national and international data re-
positories have core streams of income from research 
funders, these sources of income are usually short-
term and may be vulnerable to change in priorities 
or in responsibilities. The Organisation for Economic 
Co-operation and Development Global Science Fo-
rum is working with partners on two projects relat-
ed to Open Data for Science, one on the sustainable 
business models for data repositories and a second on 
international coordination of data infrastructures.46
6. To ensure more effective and widespread sharing of IPD and 
other data objects, organisations should be encouraged to re-
vise their policies to allow wider data reuse.
Sometimes local policies, implemented by research 
institutes and universities, may restrict data sharing 
possibilities for the data generators. These policies 
can derive from a variety of historical beliefs, includ-
ing a general distrust of data reuse, perhaps negative 
prior experiences, worries about academic competi-
tion, and concern over ownership and copyright is-
sues.47 But such beliefs are incompatible with the new 
global attitudes towards data sharing and reuse, and 
institutional policies should be reviewed to try and 
ensure that such barriers are removed.
7. Data sharing should be prospectively planned, described 
within a designated section of the trial protocol and sum-
marised in the relevant section of the trial registration record.
To ensure data sharing is considered from the begin-
ning of a trial, it should be included within the trial 
protocol. This is also suggested by other initiatives, for 
example in ref 17, and mentioned as a standard item 
in protocols for interventional trials by the standard 
protocol items: recommendations for interventional 
trials (SPIRIT) guideline, under ‘Dissemination pol-
icy’:
‘The protocol should indicate whether the trial pro-
tocol, full study report, anonymised participant-level 
dataset, and statistical code for generating the results 
will be made publicly available; and if so, describe the 
timeframe and any other conditions for access’.48
The description of how IPD will become accessible 
should therefore be much more than a vague state-
ment of intent. It would be useful also to include this 
information in the trial’s registry entry. WHO-adopt-
ed registries, such as  ClinicalTrials. gov and interna-
tional standard randomised controlled trial number 
(trial registry) (ISRCTN), have started to include 
basic information on publication and dissemination 
plans and availability of IPD. Following an Interna-
tional Clinical Trials Registry Platform (ICTRP) reg-
istry network meeting in 2017, it is expected that new 
data elements will in time be collected by more regis-
tries and displayed through the WHO portal.
8. All the trial documents (eg, participants’ information leaf-
let, contracts, consent forms, ethical submission documents) 
should be written taking into account the planned data 
sharing strategy.
As a consequence of planning data sharing from tri-
al inception, other documents can be written to take 
that data sharing into account. Participant informa-
tion leaflets should summarise the plans for data shar-
ing, including the use of external repositories, and 
consent forms should include the relevant requests 
for consent (see following section on consent). The 
data management plan, as well as other documents 
submitted for regulatory and ethical review, should 
refer to the planned data sharing strategy and related 
actions. It is not yet the case that ethical approval is 
contingent on planned data sharing, but we suggest 
that data sharing plans should be open to ethical scru-
tiny. Ethics committees could play an important role 
in facilitating responsible data sharing, for instance 
by assessing plans and ensuring that appropriate in-
formation and consent forms are used.49
9. To help support the implementation of data sharing within 
trial planning, services providing support and storing ex-
ample documents should be provided.
As a relatively new activity, planning for data sharing 
may be difficult for many researchers. Having exam-
ple documents and templates (eg, of consent forms 
and protocol sections) may therefore be a useful 
practical step in promoting data sharing as a normal 
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trial activity. The provision of advisory services that 
can make such material available may also be useful. 
There is no suggestion that each institution should 
develop its own service, but an organisation acting at 
national or supranational level could usefully gather 
and disseminate examples of good practice.
10. The time for making IPD data and documents available for 
reuse will vary, but times should be monitored and investi-
gated to identify and normalise reasonable expectations.
It is difficult to make a statement that is too prescrip-
tive about the timing of ‘release’ of full IPD data sets 
for reuse. Other initiatives have attempted to define 
timelines: for example, the Institute of Medicine re-
port suggested that clinical trial data that will not be 
part of a regulatory application be made available for 
sharing no later than 18 months after study comple-
tion.15 The ICMJE originally suggested that data un-
derlying the results presented in a journal paper be 
shared no more than 6 months after publication,21 
although more recently, perhaps mindful of some of 
the practical issues we discuss in this paper, they have 
provided much more flexible guidance.50
We believe the goal should be to make trial data and 
documents available in a timely manner. But the ex-
act time will depend—for instance—on the possibil-
ity and timing of publications by the primary investi-
gators, the complexity of the study and any associated 
substudies, the nature of the documents or data, the 
amount of analysis and preparation the data might 
require, and the access regime under which it is 
planned to make it available.
There is an expectation that most trial documents 
(other than those describing the aggregate results, 
such as a clinical study report), could and should be 
released soon after the end of data collection. For 
the IPD data sets, however, we believe investigators 
should be confident that they have completed their 
own planned authorship activity before making the 
whole of the IPD data set available. We think it rea-
sonable, however, to expect de-identified data sup-
porting a specific published paper to be available rel-
atively quickly, normally within 1 year of that paper’s 
publication. In addition, although different portions 
of the data set derived from a trial may be released 
at different times, we believe (along with the ICM-
JE50) that investigators should clearly indicate when 
they anticipate all the data will be released. In other 
words, the data sharing plan should include a time 
limit, available for inspection at the beginning of the 
study and for comparison, with actual data release, 
after the study has finished.
It will be important in the future to monitor when 
IPD is made available, and the access regimes that 
are used, comparing the reality with the data sharing 
plans originally proposed. Such monitoring will in-
evitably require support and funding from research 
infrastructures, but it will be necessary to identify not 
just the volume, nature and timing of data reuse, but 
also the technical, attitudinal and financial barriers 
that might impede it. That will facilitate both target-
ed input to minimise those barriers, and lead to a 
better, shared understanding of what are reasonable 
expectations for the timing of data release.
COnsent fOr DAtA shArIng
P2: IPD sharing should be based on explicit broad 
consent by trial participants (or if applicable by their legal 
representatives) to the sharing and reuse of their data for 
scientific purposes.
The process of informing trial participants about possible 
sharing of their data, and then gaining their explicit 
consent to it, is of fundamental importance, and is 
normally a prerequisite for the sharing of pseudonymised 
data (ie, data that have been de-identified but that can 
still be linked back to individuals using additional but 
separately stored material—see the glossary in onlinesup-
plementary appendix 2 for further details).
Data sharing activities that are an integral part of a 
trial (eg, data transfer between collaborating groups) 
can be anticipated and described in the information 
given to participants, and so can be included within the 
informed consent for trial participation. But the nature, 
purpose and destination of IPD sharing that may occur 
after the trial completes are impossible to predict. By defi-
nition, therefore, any consent for this secondary use of 
data cannot be fully ‘informed’. Instead what should be 
sought from the participant is a ‘broad’ consent to their 
data being shared, with the caveat that it should be shared 
only for scientific purposes.
It is worth noting that the European General Data 
Protection Regulation’s (GDPR)1 requirement, that the 
data subject be fully informed about the purpose of data 
processing at the time of data collection, is less strict when 
it comes to scientific research. For instance, Recital 33 of 
the GDPR suggests that:
It is often not possible to fully identify the purpose 
of personal data processing for scientific research 
purposes at the time of data collection. Therefore, 
data subjects should be allowed to give their consent 
to certain areas of scientific research when in keeping 
with recognised ethical standards for scientific 
research. […]
The EU clinical trial regulation 536/2014 also refers 
to reuse of data from clinical trials for future scientific 
research, underlining the importance of the consent to 
use data outside the protocol of the clinical trial, the right 
to withdraw that consent at any time, and mechanisms 
to review that secondary analyses are appropriate and 
ethical (paragraph 29 of the preamble).51
Broad consent should still be given with as much infor-
mation as is practicable, for instance about the reasons 
for data sharing (in general, not as it might relate to their 
own data) and the nature of any preparation of the data 
prior to them being shared (for instance a statement 
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saying that it will be de-identified). Like all consent, to 
be meaningful it must also be given without coercion, 
however unintended that coercion might be. In partic-
ular, the consent should be explicit and clearly separate 
from any other consent. It cannot be implied by the 
consent to participate in the trial, because it is a separate 
activity and not part of that trial (although as explored 
in the discussion section, we accept that not everyone 
holds this view). Nor can consent to data sharing be 
used as an inclusion criterion for the trial, as this implies 
coercion.
It has been argued that if participants need to provide 
separate consent for data sharing, there is a danger that 
any shared data set will differ from that used in the orig-
inal analysis, that is, that participants who do not agree on 
sharing their data are systematically different from those 
who agree, producing a bias in the population under 
study. Because of this it is argued that consent to data 
sharing should be assumed unless an ‘opt-out’ option 
is exercised. One difficulty with the ‘opt-out’ approach 
is that this is not a valid concept in many EU countries, 
but the more fundamental problem is that it is not a 
form of explicit consent. In fact, it would create only an 
implicit consent, and we believe that would form an inad-
equate basis, legally and ethically, for later data sharing 
actions.
11. Gaining consent to secondary use of data should 
become a standard procedure, to provide legiti-
mate sharing of data collected during clinical 
trials.
This recommendation follows as an obvious con-
sequence of the principle above. Gaining explicit 
broad consent is the only simple way to avoid the le-
gal complexities of attempting to share data where 
such consent does not exist. Even though, in some 
jurisdictions, explicit consent for the secondary use 
of fully anonymised clinical trial data may not be le-
gally necessary, there are problems with what ‘fully 
anonymised’ might mean in practice. In addition, 
the legal context continues to evolve, for instance 
with the introduction of the GDPR1 in Europe, and 
future national modifications and judicial interpre-
tations of that regulation, and it is difficult to pre-
dict possible limitations on the use of data without 
consent. Beyond this pragmatic requirement for 
gaining consent, there is also an ethical impera-
tive to be open and transparent with participants 
about the possible use of their data, which should 
make seeking explicit consent for data sharing 
mandatory.
12. Normally, the explicit consent for data sharing should be 
provided at the same time of the informed consent for the 
clinical trial participation.
Although separate, the consent to IPD sharing 
should normally be obtained at the same time as the 
consent for participation in the trial. This makes the 
whole process more practical and less of a burden 
for both investigators and participants. There will be 
some circumstances when this is difficult (eg, emer-
gency care situations), and the consent to secondary 
use of data may therefore necessitate a separate con-
sent event.
13. The consent for secondary use of IPD should be as broad as 
possible.
The broad consent given should allow the future sci-
entific use of the data. Restricting future secondary 
use to research in particular disease areas or types 
of research, for example, should be avoided, be-
cause it will be impossible to predict the source of 
requests for data access and how they might be cat-
egorised. The concept of broad consent comes from 
the field of biospecimens and biobanks, where it is 
generally accepted from an ethical perspective, es-
pecially when there is a process of oversight and 
approval of future research activities.52 We there-
fore recommend a broad consent for ‘data sharing 
for scientific purposes’, which explicitly excludes 
any other, for example, for insurance or forensic 
purposes.
14. An appropriate consent process for secondary use of data 
should ensure the following:
a. The reasons for asking about data sharing, and 
the general benefits of data sharing in clinical re-
search, are made clear to the trial participant.
Although it is envisaged that most trial partici-
pants will willingly consent to data sharing, it is 
still important that potential trial participants 
are informed about the general benefits of such 
sharing for science and medical practice. This 
information is likely to be part of the patient 
information sheets.
b. The nature of data preparation, storage and ac-
cess is explained to the trial participant, so far as 
they are known at the time the patient documents 
are produced.
It will also be important to describe, in broad 
terms, how and where the data will be stored, and 
how confidentiality will be maintained (eg, by 
de-identification measures). Even though consent 
for data sharing cannot be fully informed, because 
the nature, purpose and destination of data 
sharing that may occur after the trial completes 
are impossible to anticipate, efforts should still be 
made to describe the measures that will be used 
to protect participant privacy, the type of requests 
that will be considered and the scrutiny to which 
they will be subjected, and so on. In other words, 
the consent should be as informed as possible. 
Obviously, this requires at least the outlines of 
a data sharing strategy to be in place from the 
outset of the trial.
c. The information provided should be clear and 
concise, and couched in vocabulary understood 
by the trial participants (or if applicable their le-
gal representatives).Further research is needed 
to identify appropriate ways of presenting this in-
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formation to the participant, and good practise 
needs to be defined and implemented.
d. The explicit consent for data sharing should be 
reflected in the layout of the consent forms.
A request for consent to secondary use of data 
must be clearly distinguishable from any other 
matters in the informed consent document. This 
does not mean, however, that separate consent 
forms or documentation are required to handle 
data sharing—the different signature sections can 
be integrated into one document, and it would 
normally be easier to do so.
e. Although data participants should have the right 
to withdraw their consent for data sharing, the 
practical difficulties in implementing this should 
be made clear.
There is no dispute that the right to withdraw 
consent to data sharing must be respected. In legal 
terms, the need for a consent is normally coupled 
with a corresponding right to withdraw that 
consent, and this is acknowledged, for example, 
in the GDPR (article 7.3).50 As long as the stored 
data are still pseudonymised (ie, a participant’s 
data can be identified), a participant’s request 
that their data be removed from the data set 
can be honoured. This might involve providing 
new versions of data sets to repositories, and be 
supported by including clauses about the manage-
ment of withdrawn consents in data use agree-
ments.53 As pointed out in the EU clinical trial 
regulation 536/2014, however, the withdrawal of 
informed consent should ‘not affect the results of 
activities already carried out, such as the storage 
and use of data obtained on the basis of informed 
consent before withdrawal’ (paragraph 76 of the 
preamble).51
The practical difficulties, and associated costs, in 
modifying data already delivered to a separate 
repository should not be underestimated, and it 
may therefore be difficult to offer the withdrawal 
option once data have been deposited. There are 
even more difficulties in withdrawing data after 
they have been shared with a secondary user—in 
fact this may be impossible in practical terms. The 
key point is that any limitations to withdrawing 
consent for data sharing should be made clear in 
any explanatory material in the patient informa-
tion sheets.
DAtA PrePArAtIOn: PrOteCtIOn Of trIAl PArtICIPAnts
P3: IPD made available for sharing should be prepared for that 
purpose, with de-identification of data sets to minimise the 
risk of reidentification. the de-identification steps that are 
applied should be recorded.
Shared IPD from clinical trials used for further scientific 
research should always be de-identified and either pseudony-
mised or anonymised (see glossary in online supplementary 
appendix 2). All three are important concepts, although 
only the last two are used within EU law. Any consideration 
of data preparation requires a shared understanding of these 
terms, so they are discussed below.
De-identification is not defined under the GDPR 
but is defined in the USA, for example in the Health 
insurance portability and accountability act (HIPAA) 
regulations.54 It means removing or recoding identi-
fiers, removing or redacting free text verbatim terms, 
and often removing explicit references to dates. Partici-
pants’ identification code numbers are de-identified by 
replacing the original code number with a new random 
code number. It is used in this document to indicate 
that identifiers have been removed from a data record 
but does not necessarily mean that the data record 
meets the requirements of being pseudonymised or 
anonymised according to GPDR.
Pseudonymisation means processing personal data in 
such a way that the data can no longer be attributed to a 
specific data subject without the use of additional informa-
tion, (eg, a data set linking trial identifiers to identified or 
identifiable persons) provided that such additional infor-
mation is kept separately and under controlled access, to 
prevent the data being identifiable in isolation. Although 
theoretically such information could be used to match 
against a clinical trial data set and identify individuals, 
this would be very difficult in practice and could only 
occur if there was a major breach of security.
Anonymisation is a technique applied to personal data 
to make it, in practice, unidentifiable. Full (complete, 
or irreversible) anonymisation involves de-identification 
and the destruction of any link to an identified or iden-
tifiable person via a pseudonym. Effective anonymisation 
can be applied to a specific data set, by de-identification 
and removal of the link to a pseudonym, coupled with 
the use of new identifiers for individuals. There is no 
link maintained between these new internal identifiers 
and any others that might exist, for example in another 
pseudonymised data set (eg, pseudonymised data set of 
the sponsor).
Thus, if a de-identified data set is pseudonymised, the 
participants in it can be identified only by those who 
possess the relevant ‘additional information’. If a de-iden-
tified data set is fully anonymised, the participants cannot 
be identified by anyone (leaving aside the theoretical 
possibility of matching against the original clinical data). 
If a de-identified data set is effectively anonymised, there 
remains only the very small possibility of matching the 
data against a corresponding but pseudonymised set, if it 
is accessible (it should not be), but the matching cannot 
be guaranteed, especially if the participants share many 
of the same data values.
15. Before data can be shared, they should be de-identi-
fied, removing possible identifiers to minimise the risk of 
reidentification.
Adequate de-identification is one of the key determi-
nants of successful protection of study participants 
from reidentification. The level of de-identification 
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required for both pseudonymised and anonymised 
data is the same. In all cases it should provide a 
high level of assurance that the data content, in and 
of itself, cannot be used to identify the individuals 
within the data set. Other policies and procedures 
(eg, the use of a data use agreement) also provide 
protection against reidentification, but de-identi-
fication is a necessary prerequisite and should be 
applied to all data made available for secondary 
use.
16. Shared data should remain pseudonymous unless that is not 
allowed by the relevant legislation. Additional information 
that may allow reidentification should be stored securely and 
not shared.
Sharing of pseudonymous data is recommended and 
should be the normal expectation. Clinical trial data 
are pseudonymous when collected, or can be easily 
turned into pseudonymous data within the research 
unit, by processing of the data set and splitting off 
the identifying data points. It would be rare for tri-
al data to become fully anonymised, or at least not 
until many years have elapsed after data collection. 
There are legal obligations on sponsors to maintain 
the pseudonymised data set, as collected, for many 
years, the exact time depending on national regula-
tions. In addition, the original investigators, or their 
institution, may want to use the pseudonymising key 
in case they wish to return to the same participants 
to carry out further investigations (assuming they 
have the ethical approval and/or explicit consent 
to do so).
The principal options for sharing data are therefore 
(1) to share the pseudonymous data set, but not the 
pseudonymising code; or (2) effectively anonymise 
the data set before it is shared, by replacing the iden-
tifiers used in the trial with another independent set 
and not retaining any linkage information between 
the two.
The advantage of sharing pseudonymised data is 
that, if the secondary user discovers good reasons for 
clarifying, expanding or matching some of the data, 
or even for further investigations with some of the 
source population, they can contact the holders of 
the pseudonymous data and discuss if and how this 
might be achieved, because the individual partici-
pants are still (indirectly) identifiable. This does not 
mean that identifiable or identifying information 
would be transferred to a secondary user, unless there 
was explicit consent from the participant for this to 
happen (although this seems unlikely to be given). It 
only means that if a case can be made for identifying 
the individuals in the data set, it is at least possible to 
discuss the possibilities of doing this, including possi-
bly returning to the individuals concerned to request 
additional consent.
17. Standard procedures and techniques for de-identification 
should be applied, whenever they exist, and fully document-
ed to ensure transparency and reproducibility.
De-identification should be consistent with current 
standards, guidelines and policies provided by official 
bodies and scientific organisations.55–62 Techniques 
and guidelines for de-identification of health data 
exist and are becoming more common in research 
(eg, ref 63). The record of de-identification should 
be stored, most usefully alongside the de-identified 
data set as another piece of metadata. To make it 
easier to review the de-identification that has oc-
curred, we need a standardised, and ideally machine 
readable, way of describing those de-identification 
actions.
18. An assessment of the residual risks for reidentification of 
participants in de-identified data sets should be performed.
Under the GPDR, at least in Europe, there is obliga-
tion on the data controller to carry out a data pro-
tection impact assessment (DPIA), to ‘evaluate…
the origin, nature, particularity and severity’ of the 
‘risk to the rights and freedoms of natural persons’ 
before processing personal data. The impact assess-
ment ‘should include the measures, safeguards and 
mechanisms envisaged for mitigating’ the identified 
risks. This implies that the initial de-identification 
of data, for instance prior to its deposition in a re-
pository, should be accompanied by such an im-
pact assessment, ideally included within the record 
of de-identification described in recommendation 
17.
In addition, at least in a managed access environ-
ment, assessments of reidentification risk should be 
made when data are requested for secondary use, 
because a full risk assessment will be sensitive to the 
particular context of the planned usage, in particular 
any data use agreement. If the data have already been 
adequately de-identified, such a risk assessment may 
be relatively light, and in some cases, may be delegat-
ed to the repository managers.
Practical guidance is available on managing de-iden-
tification and assessing the associated risks. For exam-
ple appendix B of the Institute of Medicine’s paper on 
data sharing,14 ‘Concepts and Methods for De-identi-
fying Clinical Trial Data’, provides a useful overview of 
both the assessment of risks and strategies to mitigate 
them, focused on but not restricted to the US context. 
In Europe, the article 29 data protection working par-
ty has produced a detailed guide about the DPIA and 
how it should be applied.64 But it should be noted 
that, at this point, it is unclear how different national 
jurisdictions may interpret the requirements for im-
pact assessment in the specific context of the sharing 
of clinical research data. The legal responsibilities of 
the trial sponsor, as the data controller, and if and 
how they might be delegated to others, remain to be 
clarified.
19. Reidentification of data subjects should always be forbidden.
Attempted reidentification of data subjects should 
be explicitly prohibited in any formal data use agree-
ment. Even when a binding agreement does not exist, 
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attempting reidentification is likely to be illegal, and 
in any case should be subject to sanction. The sanc-
tions that might be applied could be organisational 
(eg, for serious misconduct) and financial (eg, loss 
of access to further funding) as well as legal (eg, for 
breach of contract).
20. In cases where no explicit consent for data sharing was ob-
tained from the trial participants, data sharing may still be 
possible if the data are prepared, and data requests processed, 
in ways that maintain legal compliance.
Data that do not carry an explicit consent to data shar-
ing (as from many past and current trials) could still 
be shared in circumstances where national or other 
regulations allow for exceptions to the normal restric-
tions on data sharing, for instance where obtaining 
consent is seen as too impractical for researchers or 
too burdensome for participants, and the risks are 
assessed as low. In such circumstances, it is anticipat-
ed that the proposed sharing request and data use 
may need the involvement of ethical committees or 
other review boards, dependent on national systems. 
In addition, the data may be required to undergo an 
increased level of de-identification, and the data use 
agreement may impose greater restrictions on data 
access.
Effective anonymisation may also be an option, al-
though there has to be a mechanism to agree that 
anonymisation has been truly achieved. If that is the 
case the data protection regulations no longer apply. 
Anonymising data will itself usually be seen as data 
processing, and thus covered by data protection reg-
ulations. The anonymisation would therefore have 
to be done by someone who had been authorised to 
process the data.
The difficulty is that many of the issues surrounding 
the secondary use of data without explicit consent 
have yet to be clarified, and will need (in Europe) 
the further interpretation by national authorities 
of the requirements represented by the GDPR, in 
the specific context of clinical research data. The 
emphasis in future trials should be on avoiding 
this issue altogether, by a rapid and widespread in-
troduction of explicit consent procedures for data 
sharing.
21. Services to support de-identification of data sets, which could 
range from simple guidance, through consultancy, and on to 
performing and documenting the de-identification process, 
should be established.
To ensure good practice in this area, it would be 
useful to identify existing centres of expertise and/
or develop central services that could provide robust 
de-identification practices, documentation and/
or review. Such services could make use of the exist-
ing guidelines and good practices, as for example 
those from the Council of Canadian Academies,61 
and develop them further in the particular context 
of clinical trial data. In time, such good practices 
could be disseminated to research units so that they 
become able to carry out their own de-identification 
measures.
DAtA PrePArAtIOn: DAtA stAnDArDs
P4: to promote interoperability and retain meaning within 
interpretation and analysis, shared data should, as far as 
possible, be structured, described and formatted using widely 
recognised data and metadata standards.
A greater use of data standards is critical to the success of 
data sharing. Without such standards, any shared data 
are harder to interpret with confidence and much more 
time-consuming, and thus costly, to aggregate. Standards 
can apply to data item definitions and codes, to controlled 
vocabularies used for categories, and even to the way data 
are structured and exchanged. The file formats used for 
storing and transferring data should also be standardised to 
make data processing easier.
It is accepted that the nature of clinical research, where 
novel interventions may be under test, means that it may 
sometimes be necessary to create new definitions and codes 
for some of the data items used in a trial. The aim, however, 
should be to make use of widely recognised data standards 
wherever possible (such as those from CDISC). Where 
new definitions are required, to support new science, they 
can and should be derived by extending existing standard 
schemes. The widespread use of data standards has a critical 
role in reducing the costs and maximising the utility of data 
sharing.
22. Data and coding standards should be built into any trial’s 
data design prospectively, from the beginning of the trial.
It is very difficult to try and apply standards and data 
definitions after a trial database has been designed 
and the data collected, or to try and change data 
structures unless a trial has been designed from the 
beginning with those data structures in mind (eg, it is 
much easier to map data to Clinical Data Interchange 
Standards Consortium - Study Data Tabulation Mod-
el (CDISC SDTM), the tabular data format used by 
the Food and Drug Administration (US) (FDA), if it 
has been collected using Clinical Data Interchange 
Standards Consortium - Clinical Data Acquisition 
Standards Harmonisation (CDISC CDASH) data 
items). Legacy data conversion can be done when 
there is value in combining data from prior trials, but 
it is resource-intensive and may compromise data in-
tegrity. The time and costs required for retrospective 
‘standardisation’ would put such an exercise beyond 
the resources of many non-commercial units. Instead, 
it is important that standards are designed from the 
start, with decisions made about the coding and oth-
er systems to be used made as part of the trial design 
process.
23. Among the various data standards available, those 
from CDISC should be considered as offering the 
best starting point currently available for defin-
ing and coding data and metadata in a consistent 
way.
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In a steadily evolving standards environment, there 
is clearly a risk attached to recommending any spe-
cific standards. Nevertheless, the work CDISC has 
done in developing standards in clinical data items 
and data structure for nearly 20 years has resulted in 
a suite of useful and harmonised data standards of 
particular relevance to clinical trial data.65 We would 
encourage researchers to examine one or more of 
these standards, which have been widely adopted 
around the globe, as a vehicle for introducing more 
standardisation into their trial data. Of course, us-
ing other recommendations and standards—for ex-
ample, core outcome sets as collected by COMET,66 
Medical Dictionary for Regulatory Affairs coding 
for adverse events67 and the eTRIKS standards for 
translational research68—can also increase interop-
erability between data and complement the CDISC 
standards.
It will also be important to develop standards further 
so that they can apply to a greater proportion of data 
from clinical practice, including working towards a 
maturation of healthcare data standards, such that 
they can be used synergistically with research stand-
ards.
24. Non-commercial clinical research infrastructures should 
actively support the prospective use of data standards, for 
instance by taking advantage of existing training, materials 
and supporting services, and expanding these as needed.
The use of data standards in non-commercial re-
search has been relatively limited up to now, and 
consequently there is a need to increase awareness of 
the different standards available and their uses, and 
develop tools and services that can help researchers 
apply them in practice. Infrastructure organisations, 
such as ECRIN and the various national networks, 
working with the standard development organisa-
tions, can play a key role in this. Support might range 
from awareness raising workshops and developing 
informational materials through to curating libraries 
of data collection instruments. For CDISC standards 
there is SHARE (Shared Health and Research Elec-
tronic Library), a tool providing access to curated 
machine-readable versions of CDISC standards and 
terminology.69
25. Non-commercial clinical research infrastructures should 
actively participate in the standards development process to 
further extend the standards as needed.
There is a need for more non-commercial research 
organisations and infrastructures to become involved 
in data standard development. In the past standards 
development has often been driven by requirements 
for submission to regulatory authorities, although, 
more recently, the process has broadened to encom-
pass standards that apply to public health and dis-
ease outbreaks, nutrition research and observational 
studies.
It will be important to continue these developments 
to ensure that standards are equally useful, and equal-
ly applicable, to both the commercial and non-com-
mercial research sectors. We recognise that increas-
ing the engagement of non-commercial research 
facilities with data standards will necessarily be a grad-
ual and long-term process, but the potential scientif-
ic benefits are too great for that engagement not to 
occur. Key to that process will be academic rec-
ognition and reward for input into standard 
development.
26. Clinical trial data sets should always be associated with 
metadata that describes the characteristics of each data item 
(eg, type, code, name, possibly an ontology reference), as well 
as the schedule and design of the trial.
As a minimum, a basic data dictionary and study 
schedule should be provided, for instance as spread-
sheets, or as an (CDISC) operational data model 
(ODM) XML file. Ideally, however, the metadata 
should include the meaning of the individual data 
items (eg, to clarify different types of blood pressure 
measurement, or the meaning of ‘clinically signifi-
cant’) either by providing brief descriptions or by ref-
erencing a published ontology. The CDISC Define.
XML metadata system provides one mechanism to re-
move ambiguity in this way. The more uniform data 
set metadata becomes, the more feasible it will be to 
build tools that can search, compare and aggregate 
data sets automatically, potentially reducing the costs 
of data reuse.
27. Data sets should be made available for sharing in one or 
more standardised file formats that can be read by a wide 
variety of different systems.
Proprietary and statistical software formats should 
be avoided. Using relatively simple and gener-
ally interchangeable file formats (sometimes re-
ferred to as transport standards), which can be ac-
cessed using a variety of file manipulation tools, 
is an important aspect of making shared data as 
accessible as possible to a wide range of potential 
users.
Any formats should, however, allow for the explicit 
preservation of structure within the data, including 
parent–child relationships. For that reason, struc-
tured text, based on XML schemas, is a particularly 
useful and generally applicable format. ODM XML 
has the advantage of supporting an audit trail to en-
sure data traceability and provenance.
rIghts, tyPes AnD MAnAgeMent Of ACCess
P5: Access to IPD and trial documents should be as open as 
possible and as closed as necessary to protect participant 
privacy and reduce the risk of data misuse.
28. A range of access types to shared data and documents is 
expected and encouraged, including different forms of con-
trolled access.
The guiding principle we encourage is that IPD and 
associated documents should become as openly ac-
cessible as possible. Although we believe most trial 
documents should be openly accessible without re-
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strictions, we acknowledge that IPD may pose con-
cerns for the data controllers (the sponsors)—over 
protecting participant privacy—and the data gener-
ators (the investigators)—for instance over possible 
misinterpretation of the data. Given the current lack 
of established standards surrounding IPD sharing, we 
believe a range of access models to data sets will be 
inevitable. We would recommend, however, that for 
IPD the secondary user should as a minimum identify 
him or herself, and agree to some basic conditions of 
data use (see recommendation 29).
Depending on several factors (eg, the nature of the 
consent obtained, risk of reidentification, concerns 
about stigmatisation, misuse of information, incor-
rect analysis and so on), access models may range 
from publicly accessible web-based systems, with 
the possibility of downloading data sets, through 
various types of request/review mechanisms that 
may or may not allow data download. A granular-
ity of access may also be applied to different parts 
of the same data sets, as some piece of information 
may be more sensitive or difficult to handle than 
others.
We acknowledge that the issue of who is responsible 
for choosing one access model over another is not 
yet resolved. Data generators will usually be most fa-
miliar with the potential value of the data, as well as 
the risks associated with its misuse, so should have a 
role in the definition of access schemes. Data reposi-
tories may also have a role in this process, if some or 
all aspects of access control have been delegated to 
them by the data controller. The final goal should re-
main, however, the maximisation of the value of data. 
It would therefore be useful to establish mechanisms 
to monitor data access regimes, and where neces-
sary to identify and help modify any overprotective 
schemes.
29. Access to IPD should always be accompanied by a statement 
of compliance with basic rules designed to promote a fair 
sharing of data.
We believe that all secondary data users should ac-
knowledge and agree to some basic rules of data use. 
For instance, they should identify themselves (includ-
ing validating their email address using a call-back 
and confirmation process), not attempt to reiden-
tify participants, make the results of any secondary 
analyses public and cite the data source correctly in 
any published work. The definition of international 
standard practice for data sharing would usefully clar-
ify these basic rules, and help to alleviate the fears of 
researchers about possible problems. At its simplest 
compliance with the basic rules of reuse could be 
signalled by completing a web-based form. More de-
tailed attestation or formal agreement is likely to be 
needed in some situations, for example if the original 
consent to secondary use mentions possible restric-
tions, data sensitivity is high, or the data generators 
are concerned over misinterpretation.
We acknowledge that some data repositories cur-
rently host de-identified clinical trial data sets that 
are available for immediate perusal or download 
without any type of restriction or registration.70 71 Al-
though this is clearly possible, we reiterate that the 
secondary user should normally be asked to comply 
with some core principles, as an important aspect of 
maintaining the transparency of the data sharing sys-
tem and making data sharing more acceptable to all 
stakeholders.
30. Boards overseeing the data sharing process may be estab-
lished, ideally at the level of data repository. These boards 
may provide advice on ethical and legal issues that may arise 
in data sharing and, for controlled access, may be responsi-
ble for the management of data access requests.
The presence of a board that oversees the overall 
data sharing process and, if applicable, evaluates 
data access requests has been widely advocated. The 
role and responsibilities of such boards may vary. As 
an initial step, we envisage the creation of boards of 
experts (‘access advisory committees’ or some equiv-
alent term) who can provide advice and support 
to data generators and repositories. Ideally, these 
boards would be established by repositories or groups 
of repositories.
In the same way that data generators are encouraged 
to use suitable repositories for storage, and for the 
same reasons of providing continuity of data manage-
ment in the longer term, we encourage the delega-
tion of access management to the repositories and 
their boards. When a controlled access model applies 
and a formal evaluation of the data request applica-
tion exists, we encourage a process where the assess-
ment of the scientific merit, potential impact and ap-
propriateness of the proposed secondary analyses is 
performed by independent data access boards. These 
boards could also assess and ensure that the data gen-
erators were fully cited and recognised, although this 
would only work if mechanisms to track citations and 
highlight when recognition was not given were in 
place.
31. Irrespective of the tasks delegated to these boards, transparen-
cy in their mandate, procedures, composition and expertise 
is essential.
Whatever the exact mandate of any particular board, 
it will be important that its work is transparent and 
that its membership is known. It is important that any 
board includes a wide range of expertise, including 
representatives of citizens and patient groups. Any 
possible conflicts of interests (including non-financial 
ones) should be declared and managed. The evaluat-
ing criteria and process should be public, as well as ag-
gregated metrics about the reasons for accepting and 
rejecting particular requests. This will ensure the trans-
parency of the decision process and be of aid to future 
applicants.
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P6: In the context of managed access, any citizen or group 
that has both a reasonable scientific question and the 
expertise to answer that question should be able to request 
access to IPD and trial documents.
32. The right to request access to data should not be limited to 
specific professions or roles.
As a general principle, access to data should not be 
limited to a specific type of requester or profession-
al profile. In cases where the access model includes 
a formal evaluation of a data access application, the 
scientific question to be addressed, and the ability of 
the requesters to answer that question, is more rele-
vant to the assessment of data requests than the re-
questers’ current job roles. Data could be sought, for 
example, by students and science journalists as well as 
by active researchers or reviewers. The requesters or 
their team would, however, normally need to demon-
strate the ability to draw scientifically literate conclu-
sions from the data.
If access is formally managed, the data requester 
may need to provide a research protocol and analy-
sis plan, including information on data management, 
data storage and plans for publication of the results 
of the reanalysis. The requester should also provide 
information on his/her (or team) expertise, possibly 
making use of persistent digital identifier systems (eg, 
open researcher and contributor ID (ORCID)).
Consideration of access requests should not, in prin-
ciple, be influenced by whether the proposed second-
ary reuse is associated with a potential commercial 
benefit, directly or indirectly, in the short or the long 
term. There is, in any case, often difficulty in clearly 
differentiating ‘pure’ from ‘applied’, or ‘commercial’ 
from ‘non-commercial’ research.
33. Collaboration between data providers and secondary data 
users could be an added value in data sharing. However, it 
should not be a prerequisite for data sharing.
Several benefits can arise from the involvement of the 
data generators in the reuse of data. The original in-
vestigators can share key insights with the secondary 
users about the study, its data and analysis, reducing 
the possibility of misinterpretation of data. This kind 
of cooperation may therefore substantially enhance 
the quality of secondary data usage and make it more 
efficient.
In the model of data sharing envisaged in this doc-
ument, there is, however, no necessity to involve the 
data generators (as was often the case in the past, 
when data were shared within research collabora-
tions), and whether such involvement is planned 
should not influence, in a controlled access envi-
ronment, the data access decisions. If there is active 
participation by the original data providers, then 
coauthorship in the publication resulting from the 
reuse will normally be appropriate, following the es-
tablished rules on authorship.40
Even if not directly involved in the secondary use, 
it is reasonable that data generators (assuming that 
they have not made the data access completely open) 
should have the option of being informed about 
who is accessing data, or requesting such access, and 
when. This would be possible if secondary users are 
always asked to identify themselves (see recommen-
dation 29) and could be part of a formal agreement 
between data generators and repositories (see recom-
mendation 42).
34. The results and methodology of further analysis of data and 
documents should themselves be publicly available and de-
posited in an appropriate repository, whether or not they are 
associated with published papers.
Data users should agree to make the methods and 
results of their secondary analyses publicly available 
not only through scientific publications (that may 
or may not be prepared and, if prepared, that may 
or may not be accepted for publication) but also by 
depositing them in a repository and making them 
discoverable. This will be important to provide fur-
ther examples of effective data sharing and allow any 
conclusions from secondary use to be examined by 
others.
P7: the processing of data access requests should be explicit, 
reproducible and transparent but, so far as possible, should 
minimise the additional bureaucratic burden on all concerned.
Within a formally controlled data access system, that is, one 
requiring explicit request and evaluation of that request, the 
process through which data can be accessed should be clear, 
reproducible and transparent. Inconsistent decisions should 
be avoided and criteria should be explicit.
35. To simplify the request process, repositories should be encour-
aged to make the interface presented to secondary users as 
consistent as possible.
Processes, information requirements and proformas 
should be the same or very similar between different 
repositories, to make life simpler for all concerned 
but especially the secondary data users. It may even 
be possible to develop a common ‘access request 
pipeline’, especially for smaller repositories, so that 
associated costs could be shared, even if each repos-
itory retains the rights to individually approve or re-
ject requests.
Taking this one stage further, it should also be possi-
ble to share boards across repositories. The existing 
CSDR scheme provides a similar approach, with data 
generated and stored by different commercial com-
panies, but with the Wellcome Trust orchestrating 
the process and supporting a common Independent 
Review Panel.23 There are questions about how such 
a scheme could be funded in the non-commercial do-
main, and how the membership of a common review 
board could be made acceptable to many different 
users. Despite these issues, however, this approach 
could offer considerable simplification for secondary 
users, and reduce the bureaucratic burden on repos-
itories.
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36. The implementation of a standard terms of use agreement, 
a ‘data use agreement‘, specifying the conditions for data 
access and reuse, is encouraged.
Such an agreement should not constitute an obstacle 
to data sharing—instead it should facilitate it by en-
suring that the rights, roles and responsibilities of all 
parties are defined.
Templates for data use agreements (along with an 
explanation for the information requested) could be 
developed, made public and shared by several reposi-
tories to simplify the access request process.
37. An appropriate data use agreement should include at least 
the following aspects:
a. Partners and bodies involved.
Clearly identifying the parties and their role and 
responsibilities.
b. Definitions.
Where there is any real or potential ambiguity, 
terms should be defined.
c. The purpose of the request and possible restric-
tions.
A description of the intended, agreed use and any 
limitations to that use (eg, restricted to research 
in a particular disease area). This section should 
also include definitions of inappropriate use of 
data and any restrictions on how the data can 
be used (eg, distribution of data to third parties, 
attempt to reidentification).
d. Agreement to acknowledge and give credit to the 
original data generators.
e. Public dissemination of the results of the reanal-
yses.
An agreement to provide public deposition of 
results, often but not necessarily in the same 
repository as the source data.
f. Consent issues.
How consent for IPD sharing has been managed, 
for example, a description of the consent being 
used to justify the data sharing (or in the absence 
of explicit consent a description of the regula-
tions under which sharing is taking place and how 
they have been met).
g. Terms and conditions of control over the data 
within the requesting organisation.
How the data will be managed and stored in 
the organisation of the requester(s), assuming a 
data download, and the measures to be taken to 
ensure appropriate access and security.
h. Terms and termination of the agreement.
Defining the period during which the agreement 
is effective. Specifying the conditions under which 
the agreement can be terminated before the 
contractual duties have been fulfilled (eg, breach 
of data sharing code of conduct and so on). How 
the data will be managed once the agreement 
is terminated (eg, will data be returned to the 
provider or destroyed?).
In order to allow data sharing as open as possible, unnec-
essary restrictions due to intellectual property issues, 
patents and licences should be avoided. Data and objects 
should be deposited in repositories under licences that 
maximally support data sharing, for example, with Crea-
tive Commons, that allow others, in legal terms, to both 
use "works" and to make "derivative works" from them.
38. Tools should be developed to support the implementation of 
common metrics across different data sharing platforms and 
repositories, publishing these under a common portal.
Examples include the numbers and types of request 
and approval data, together with reasons for not pro-
viding access, and summary data (including links) 
on the published papers resulting from reuse of data 
and documents. This is an important aspect of main-
taining transparency across the entire data sharing 
process.
39. Mechanisms to collect and display user feedback, about the 
process of accessing data or data sharing in general, should 
be developed and implemented by repositories themselves or 
by third parties.
Such feedback could be a useful complement to the 
data described in recommendation 38, helping to im-
prove transparency and increase user involvement, 
as well as providing direct feedback to repositories. 
Implementation could be by individual repositories 
or by an external service, or by some combination of 
the two.
DAtA MAnAgeMent AnD rePOsItOrIes
P8: besides the IPD data sets, other clinical trial data objects 
should be made available for sharing (eg, protocols, clinical 
study reports, statistical analysis plans, blank consent forms) 
to allow a full understanding of any data set.
In any discussion about data sharing the emphasis is natu-
rally on the data sets themselves. But to fully understand 
that data requires the context, purpose and timing of 
the data collection to be clear, as well as the processing 
and analysis that were originally carried out on that data. 
That in turn demands that protocols, analysis plans, study 
reports, case report forms (CRFs) and so on also be avail-
able for sharing, and need to be managed as available 
‘data objects’—preferably within designated repositories 
(as in the following principle 9). If not, there is a danger 
that the data, considered in isolation, could be misinter-
preted. For both data generators and secondary users, 
therefore, it is important that the material that needs to 
be stored and managed, and potentially shared, includes 
all relevant documents as well as data sets.
P9: Data and trial documents made available for sharing 
should be transferred to a suitable data repository to help 
ensure that the data objects are properly prepared, are 
available in the longer term, are stored securely and are 
subject to rigorous governance.
There is a risk that ‘making data available for sharing’ 
could be interpreted as the original research team simply 
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agreeing to consider data requests on an ad hoc basis. We 
feel that there are several problems associated with this, 
however, and that the alternative—of data being trans-
ferred to a designated data repository—is a much better 
option. The reasons for this include:
 ► The original research team (or collaboration) will 
change its composition, or may even cease to exist, and 
it may then become difficult or impossible for data to 
be managed and requests to be properly considered.
 ► The transfer of data to a third-party repository makes 
it more likely that preparation of the data for sharing 
(eg, de-identification, provision of metadata) will 
occur, and help ensure that the data and related docu-
ments are properly described.
 ► Planning for transfer to a repository helps to explicitly 
identify data preparation and sharing costs at an early 
stage of the trial.
 ► It helps to make the data and trial documents more 
easily discoverable.
 ► It can relieve the original research team/sponsor of 
the need to review requests and even (depending on 
the arrangements made with the repository) of the 
need to make the decisions about agreeing to such 
requests.
A ‘designated data repository’ in this context may be 
one dedicated to clinical research data and documents 
on a global or regional level, a general scientific reposi-
tory, or one specialised in storing data objects related to a 
specific disease area. It may be a repository established by 
the researchers’ own institution for ‘their’ research. We 
make no recommendations about the optimum scope of 
a repository—only about the processes it employs.
40. Repositories for clinical data and data objects should be com-
pliant with defined quality criteria.
The services any repository provides should conform 
to specified quality standards, to give its users confi-
dence that their data and documents will be stored 
securely and in accordance with the specific data 
transfer agreements they have agreed. Some generic 
standards and criteria for trustworthy digital repos-
itories have been developed and are being applied 
(eg, Data Seal of Approval,72 International Council 
for Science World Data Systems,73 DIN 3164474) and 
several instruments for certification of repositories 
have been implemented.72 73 75 76
The necessity for collaboration and harmonisation 
of these different activities has been acknowledged,77 
and proposals for a unified core set of requirements 
for trustworthy data repositories have recently been 
made (International Council for Science/World 
Data System (ICCSU/WDS), data seal of approval 
(DAS)78). The available standards, requirements and 
certification instruments for trusted data repositories 
need to be examined and their applicability to clini-
cal research data objects needs to be checked. If nec-
essary, extensions or adaptions should be provided.
There will also be a need to develop or adapt sustain-
able systems to assess repositories for clinical data and 
data objects against these standards. This is all work 
still to be undertaken but, given the likely variety of re-
positories that will be available to researchers, we see 
it as a necessary part of any acceptable data sharing 
environment. Research infrastructure organisations 
can play a key role in developing and disseminating 
both the standards and the assessment systems.
41. Information about the different repositories that hold clinical 
research objects should be made available to data generators 
so that they can make an informed choice, so far as local 
policies allow.
This information should include costs as well as the 
features and access options available, and any assess-
ment against the quality standards described above. 
The purpose is simply to assist the data generators in 
their decision on where to store data objects, as well 
as to encourage some healthy competition between 
repositories. We envisage a central service giving in-
formation and contact details on the repositories 
available, similar to the data provided now by re3da-
ta for general repositories (we believe the current 
re3dataset would need substantial modification to 
support the needs of clinical researchers selecting re-
positories). Ideally the repositories themselves would 
find it beneficial to keep their records within such a 
system as up to date as possible.
42. The transfer of any data objects to repositories (including 
those within the same institution) should be subject to a for-
mal agreement that set out the roles, rights and responsibili-
ties of the data generators and the repository managers.
We would expect a data transfer agreement to ap-
ply to the transfer of data and documents to a re-
pository. In other words, the transfer should always 
be a formal arrangement, with the responsibilities 
of each party clearly set out, rather than an infor-
mal upload. Aspects that are particularly important 
include the agreed access regime for the data, the 
mechanism by which any future data sharing deci-
sions will be made and the assignment of the data 
controller role.
43. Mechanisms for implementing an ‘analysis environment’, 
allowing in situ analysis of data sets but preventing down-
loads, should be further evaluated. Such an analysis envi-
ronment should allow different data sets from different host 
repositories to be combined on a temporary basis
This would be a specialist repository facility analogous 
in many ways to the ‘glove boxes’ or analysis environ-
ments now made available for examining some phar-
maceutical research data. The process would include:
 – Gaining permissions for the temporary ‘loan’ of 
data sets from different repositories into the anal-
ysis environment.
 – Setting up a temporary IT system (virtual ma-
chine or container) with the necessary analysis 
tools included.
 – Importing the data sets as agreed.
 – Carrying out and recording the analysis.
 – Gathering the results.
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 – Destroying the temporary IT system and the data 
it contains, usually straightaway but in any case, 
according to prior agreement.
The advantages:
 – It gives the repository/data generator greater 
control over control of access and may therefore 
encourage wider and/or earlier data sharing.
 – It allows the aggregation of data from widely dif-
ferent sources, more quickly than could be done 
by multiple applications to download files.
The disadvantages:
 – It demands a more complex and expensive tech-
nical infrastructure, including a much greater de-
gree of human input for each data aggregation, 
than a system based on simple downloads.
 – It requires trust between the repository/data gen-
erator and the organisation providing the facility, 
for example about the security and access con-
trols in place.
There are also several non-trivial challenges that 
need to be overcome if this type of facility is to work 
at scale:
 – Stable application programming interface (APIs) 
need to be developed that allow data retrieval and 
access across multiple repositories.
 – Data standards need to be applied that allow in-
teroperability of the retrieved data.
 – Cloud environments need to be constructed with 
appropriate security, audits and account manage-
ment.
 – Transinstitutional (some of which may also be 
transnational) cost sharing and accounting mod-
els will be required.
These are issues being addressed in other scientific 
domains, however, and they should not be insurmount-
able within clinical research.
DIsCOverAbIlIty AnD MetADAtA
P10: Any data set or document made available for sharing 
should be associated with concise, publicly available and 
consistently structured discovery metadata, describing not just 
the data object itself but also how it can be accessed. this is 
to maximise its discoverability by both humans and machines.
We believe that there will be many different repositories 
used for clinical research data objects, complementing 
the existing systems used to index peer-reviewed papers 
and the registries that include details of the trials them-
selves. We therefore need mechanisms to support discov-
erability across this mosaic of resources. Reviewers and 
researchers need to be able to identify the data and docu-
ments related to a trial, and discover how they can access 
them, and the restrictions on use, in an efficient and 
consistent way. A metadata description of each individual 
data object is key to that requirement, as it provides a 
means by which software agents can interrogate different 
repositories and aggregate their ‘lists of contents’, to 
form a single source of information.
44. A metadata schema suitable for describing all repository 
data objects linked to clinical trials needs to be developed 
and implemented, agreed by major stakeholders and reposito-
ry managers and widely disseminated.
Such a schema should include clear identification of 
the source trial (or trials) and of the access arrange-
ments that apply, as well as a description of the data 
object itself. Within the CORBEL project, proposals 
have been made based on the widely used DataCite 
standard,79 but any such schema requires further dis-
cussion by repository managers and others, with the 
goal of agreeing a common standard.
45. Repositories with clinical research data objects should use 
this generic schema for those objects, or a schema that can 
be easily mapped to it, so that the metadata describing the 
contents of different repositories can be aggregated.
This is an ambitious goal because of the global scale 
required (to be really useful all sources of data ob-
jects need to be included), but it is difficult to see 
how any discoverability mechanism can be made sus-
tainable in the longer term without a generic schema 
being used. The alternative would require a range of 
aggregation/reconciliation techniques for different 
types of metadata, and/or need to use ‘data mining’ 
techniques to link records. This may be an option for 
legacy trials, but is of limited value in the longer term 
because it is likely to be too difficult, error-prone and 
costly other than in a pilot or research project. We 
therefore need the widespread use of the schema de-
scribed in recommendation 44, to allow automatic 
and reliable aggregation of metadata.
46. The generic metadata scheme will need to include a common 
identifier scheme for clinical research data objects. The DOI 
is recommended as the best candidate for such an identifier. 
Mechanisms should be developed to make it easy to assign 
unique identifiers to all data sets and documents that are 
made available for data sharing.
Any metadata schema needs at its core a way of as-
signing globally unique persistent identifiers to the 
objects being described. The DOI seems to be the 
most appropriate identifier to use for this, not least 
because so many existing data objects and published 
papers make use of the same mechanism. Allocating 
DOIs will have to be done as cheaply as possible, and 
various mechanisms, perhaps using the existing abil-
ities of some universities to assign DOIs, or involving 
infrastructure organisations as the source of DOIs, 
need to be explored to identify the most effective 
approach. A related issue that needs to be tackled, 
although it is outside the scope of the CORBEL pro-
ject, is the allocation of unique persistent identifiers 
for trials, although various ‘workarounds’, for exam-
ple, the use of registry IDs, are available at the mo-
ment.
47. Tools should be developed to help data generators to complete 
the metadata fields of the generic scheme described above as 
efficiently as possible.
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One could envisage a web-based system that provided 
the necessary fields and prompts and that could be 
made available to data generators. It is important that 
wherever possible it is the data generators that create 
the metadata, as only they have the full knowledge 
of the material required (although they might not 
provide the metadata until the data objects are about 
to be transferred to a repository). The advantage of 
web-based data collection is that it could also aggre-
gate the data for different repositories at the same 
time, because the data would be stored in the same 
‘back end’ database system. This would then make 
it much easier to make the data available through a 
single portal.
48. Tools should be developed to enable the regular harvesting 
of metadata data from repositories, importing that metada-
ta into a collection of ‘metadata repositories’ for clinical re-
search data objects.
As stated above, this is a key component of aggregat-
ing metadata into useful collections. Data that are not 
generated centrally will need to be imported regular-
ly, for example by using APIs to ‘harvest’ the metada-
ta at regular intervals (eg, daily). The more diverse 
the metadata the more difficult the task, and initially 
a range of such tools might be required. Over time, if 
the metadata becomes more consistent as described 
above, the software systems can themselves become 
simpler and cheaper to maintain.
49. Metadata repositories should be developed, sustained and 
connected to enable common web-based access portals to the 
underlying metadata, providing a single point of entry for 
users as well as associated search facilities.
The broader the scope of a metadata repository the 
more useful it is to its users. The concept here is of 
a global metadata repository (MDR) portal, that is, 
website, connected to a range of individual metada-
ta stores maintained by different stakeholders. If the 
metadata used has a consistent schema across the 
various systems, then the whole aggregation of data 
becomes searchable as a single resource.
50. Mechanisms to sustain metadata repositories and the portal/
search systems that connect to them in the long term should 
be developed, based on the recognition of the importance of 
such services for data sharing.
The discoverability mechanisms described in this 
section are of little use unless they can be sustained 
permanently. Pilot metadata repositories should be 
established (and existing initiatives, eg, OpenTrials,80 
supported) to allow clearer identification of costs and 
the issues with running such a service. The research 
community and governments then need to agree 
funding mechanisms and infrastructure (eg, within 
the developing EOSC) that can support discoverabil-
ity in the longer term.
DIsCussIOn
The debates around sharing and reuse of IPD from 
clinical research have expanded rapidly in recent years, 
reflecting the fact that there is now wide agreement that 
it will benefit research and thus, eventually, healthcare. 
However, many questions concerning principles and 
practice remain to be resolved. For instance, how to best 
promote and support data sharing and reuse among 
researchers, how to adequately inform trial participants 
and protect their rights, and how, where and in what 
format data should be stored, found and accessed.
This document has discussed a number of these ques-
tions, using an approach based on the ‘life-cycle’ of data 
sharing. It articulates 10 principles, developed by the 
multistakeholder group of international experts after a 
formal consensus exercise, that represent an overarching 
framework for IPD sharing and reuse. The framework 
has been further developed into 50 more detailed recom-
mendations to provide what we believe to be clear prac-
tical guidance on how best to make data sharing work.
Methodology
To tackle an issue as complex and multifaceted as sharing 
IPD from clinical trials, we first established an interna-
tional group of experts covering a broad spectrum of 
expertise and experiences from different areas (trial 
methodology and registration, research transparency 
and ethics, meta-analyses, scientific publisher, regulatory 
bodies, patient organisations, data protection and IT 
experts, standardisation bodies, and IT service providers).
Second, we applied a standard methodology for 
consensus elaboration, that is, a nominal group process 
with the support of an independent facilitator. The group 
attended three face-to-face meetings over 1 year with 
excellent participation, extensive discussion time and a 
structured decision-making process. The nominal group 
process gave all members of the task force the opportu-
nity to identify issues and then for the whole group to 
debate and vote on them.
One major issue was evident from the beginning of this 
consensus exercise. The terminology around data sharing 
is confusing and, often, the same term is used by different 
stakeholders or in different contexts (or countries) to 
point to different concepts. For instance, different under-
standing of terms such as ‘anonymised’, ‘pseudonymised’, 
‘de-identified’ or ‘metadata’ impaired discussion at times. 
For this reason, the group developed and agreed on a 
glossary (online supplementary appendix 2) to be used 
in the context of the discussion, which hopefully can be 
useful as a general reference.
Contentious issues
Consensus did not always mean unanimity. The group 
reached a common view on general principles relatively 
easily, while, as expected, some of the detailed recom-
mendations raised more discussion. In only a few cases, 
however, were clearly divergent positions held by more 
than a small number of task force members.
One was the issue of whether the consent for data sharing 
needs to be distinguished from the consent to participate 
to the trial. It was acknowledged that a separate consent 
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is often required by law, particularly in Europe, but a 
conception of data sharing as an integral part of the clin-
ical trial process prompted a substantial minority of the 
group members to propose a single consent mechanism: 
to participate in the trial and to share pseudonymous indi-
vidual data. The reasoning behind this position was that, 
ultimately, data sharing and reuse are intended to help 
improve the health of all, and the utility of data sharing 
is increased if it encompasses all trial participants. At the 
heart of the debate was the different emphasis people 
put on the autonomy, privacy and safety of the individual, 
versus the potential gains to society from increasing the 
ease and efficacy of data sharing. The majority in the task 
force felt, however, that distinct consents were necessary, 
and in any case a single consent process would be hard 
to implement within the current legislative frameworks, 
at least for pseudonymised data (see recommendations 
12 and 14). Nevertheless, it was clear that this issue raised 
considerable and passionate debate, and that it deserves 
more detailed research and discussion involving experts 
in medical ethics and law, researchers, trial participants 
and citizens.
A related issue is the question of whether, in general, 
the data that are shared should be pseudonymous or 
anonymous. As explained in recommendation 16, the 
preference of the task force was for the former, although 
anonymisation of data will be necessary where no explicit 
consent for data sharing has been obtained (see recom-
mendation 20). An argument was made that the sharing 
of anonymised data should be the norm as it is likely it 
will make data sharing more practicable and quicker to 
establish. It may be that the early years of data sharing 
will require much greater use of anonymised data, until 
explicit consent for reuse becomes more widespread. The 
question is whether this could impact the scientific utility 
of the data, largely in terms of the potential for follow-up 
work (the degree of de-identification should be the same 
for both anonymised and pseudonymised data). This will 
require further empirical investigation.
Our findings in context
In recent years, several other organisations and projects 
have developed principles and recommendations for IPD 
sharing, as summarised in table 1.
The output of our consensus exercise therefore fits 
into a context of earlier initiatives embedded in specific 
national or geographical contexts, or dedicated to specific 
stakeholders. We believe that by providing a pan-Euro-
pean perspective on the issue of IPD sharing and reuse, 
and by looking at all aspects of the data sharing ‘life cycle’, 
the current document is a useful addition to the previous 
work in this area, complementing the reports centred on 
the USA, the UK or the Nordic countries.
While elaboration of underlying principles and generic 
recommendations are important, we have tried in this 
document to move beyond that where it seemed possible 
to do so, and make more concrete, pragmatic recom-
mendations—for instance about consent structure, the 
methods required to properly prepare data for reuse or 
the content of data use agreements. We have also iden-
tified areas where more exploratory and preparatory 
work needs to be done, for example in developing quality 
standards for data repositories that hold clinical research 
data, or in the need to establish metadata systems and 
infrastructure to support object discovery. A priority 
issue within future discussions must be how to ensure 
Table 1 Main initiatives aimed at developing principles and recommendations for IPD sharing
A report by Technopolis to the Wellcome 
Trust, 201591
This described the status of existing data sharing initiatives and current research 
practices, and generated recommendations. The study was addressed to a funder, 
developed primarily by UK researchers and focused more on key considerations of 
data access.
A report from the Committee on 
Strategies for Responsible Sharing of 
Clinical Trial Data, in the USA, 201514
Endorsed by the Institute of Medicine, this report provided guiding principles 
and a framework for activities and strategies. It tried to balance the interests of 
all stakeholders and considered commercial as well as non-commercial trials. As 
pointed out in the report, many practical issues and a detailed roadmap were not 
discussed in detail.
A report from the Working Group on 
Transparency and Registration of the 
Nordic Trial Alliance, 201515
This report provided best practices and a dense set of recommendations for the 
Nordic countries, covering not only IPD but also registration and the publication of 
summary results and full reports.
Good Practice Principles for Sharing 
IPD from publicly funded clinical trials, 
by the MRC Hub for Trials Methodology 
Research, 201516 17
Endorsed by Cancer Research UK, the MRC Methodology Research Programme 
Advisory Group, the Wellcome Trust and the Executive Group of the UKCRC Trials 
Units Network. The UK’s National Institute for Health Research has confirmed it is 
supportive of the application of these practices. The document provides detailed 
recommendations from the UK viewpoint.
Principles for data sharing, by 
pharmaceutical industry bodies (PHRMA, 
EFPIA), 201420
These are principles for data sharing (rather than detailed guidelines) from 
commercial trials, together with a public commitment to making data available for 
sharing.
EFPIA, European Federation of Pharmaceutical Industries and Associations; IPD, individual participant data; MRC, Medical Research Council 
(UK); PHRMA, Pharmaceutical Research and Manufacturers of America; UKCRC, UK Clinical Research Consortium.
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the sustainability and financial support of an IPD sharing 
infrastructure in the long-term, as it was not possible to 
identify a definitive answer or model at this stage.
We have tried to ensure that the perspective and 
concerns of the researcher, whether generating data as 
a trialist or as a secondary data user, have been incorpo-
rated into the recommendations. Thus, we have empha-
sised the need to develop appropriate support systems for 
planning data sharing and for preparing data, and for 
finding and accessing the data in ways that respect the 
concerns of both generators and secondary users.
the future role of repositories
Several questions for the future concern data repositories. 
These have been recognised as useful tools in allowing 
data sharing in other scientific domains, and we urge their 
further development (see principle 9), but so far they 
have been little used for clinical trial data. The environ-
mental scan performed within the context of this project 
has shown that there are several repositories already avail-
able (eg, B2SHARE, EASY, Zenodo, Dryad, Figshare) that 
do include at least some clinical trial data sets, and several 
more are under development (eg, the MRCT’s Vivli). The 
origin, scope, policies and capabilities of existing repos-
itories are extremely heterogeneous, however, and it is 
not always clear how their business models will guarantee 
their long-term sustainability, or what will emerge as the 
most appropriate organisational model.
For instance, should the research community work 
towards fewer, larger repositories open to all types of clin-
ical trial data, or is it better served by a smaller number 
of specialist data stores, perhaps managed by the research 
communities that are generating the data? If a multi-
plicity of repositories is inevitable, as more individual 
institutions, and perhaps countries, establish their own 
data repositories, how can we make procedures and 
processes more consistent between them, and confed-
erate content—at least at the metadata level—to make it 
easier (and cheaper) for those trying to discover content?
A portal supporting identification of trial data stored 
in repositories, and providing information on access to 
that data, would make this information more discover-
able and would likely increase the reuse of data. Existing 
approaches to characterising repositories (eg, re3data) 
should be explored for suitability in the clinical research 
domain and perhaps adapted or extended. Finally, how 
should the repositories, whatever their size, be assessed 
for compliance with standards of good practice, how can 
that assessment process be financially supported, and 
how can the results of the assessment be transmitted back 
to data generators and users?
the need for empirical research
The number of empirical studies about data sharing is, so 
far, relatively small. A limited amount of data is available, 
dealing with individual aspects of data sharing (eg, surveys 
about attitudes and experiences,81 82 statistics about data 
requests and shared data,83 84 and studies of the costs of 
data preparation85). Given that the principles and recom-
mendations in our document (and similar reports) are 
largely consensus-based, further evidence gathering 
should be a priority. The topics that will need investiga-
tion or ongoing monitoring include the following:
 ► The levels of IPD and document sharing, including 
when, how and why data are made available for 
sharing, and the differences between planned and 
actual data sharing activity.
 ► The future levels of IPD and document access 
requests, and the reasons for those requests.
 ► The costs and time involved in preparing data for 
sharing, and methods of reducing these.
 ► The attitudes of different stakeholders (researchers, 
funders, patients, publishers, the general public 
and others) to IPD sharing and reuse, including the 
reasons why some people were not making data avail-
able in timely fashion.
 ► The incidence and nature of any misuse of informa-
tion or incorrect secondary analysis, not least because 
this is a reason often given for reluctance to share 
data.
 ► The types and quality of research outputs generated 
from the reuse of IPD, to highlight the value of data 
sharing.
 ► Comparisons of different access regimes (eg, open, 
free platform vs controlled access) in terms of costs, 
accessibility, usage, user feedback and others.
 ► Comparisons of the utility of different data types, 
specifically anonymised versus pseudonymised data.
 ► Comparisons of different repository systems, including 
costs, data content and compliance with standards.
Much of this work will be through traditionally funded 
and published research, examining particular aspects 
of IPD reuse. Some may examine the impact of specific 
sharing initiatives, for example, the 2016 SPRINT data 
analysis challenge organised by the New England Journal 
of Medicine.86 87 But in some cases (eg, monitoring the 
outputs generated from reuse, or collating the data 
about available repositories and the services they offer), 
it would be more useful to construct continuous moni-
toring and reporting mechanisms. Some work of this sort 
is already being carried out, for example by the IMPACT 
(IMProving Access to Clinical Trials data) Observatory,88 
but funding mechanisms need to be developed so that it 
can be expanded as data sharing grows.
It will also be vitally important to provide patient groups 
and their representatives with this empirical data, so that 
they can remain fully involved in future debates on data 
sharing, and continue to input their perspective on the 
reuse of data.89
the need for standards and a global perspective
One of the recurrent themes in the current document 
is the need for standards and standardised processes: for 
instance, for data and metadata, for repositories, for ways 
of de-identifying data, for processing request applica-
tions and for data use agreements. The use of standards 
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is seen as critical in reducing costs and increasing confi-
dence in the systems and data in use, and it will therefore 
be important that non-commercial researchers involve 
themselves in the continuing development of standards 
of all types. It is also important that standards and stan-
dard processes are as global as possible.
Data sharing is, intrinsically, like science in general, an 
activity with global scope. A global perspective is therefore 
the best way in which to develop efficient and effective 
standards, processes and systems. We appreciate that is 
easy to say but often very difficult to implement, not least 
because very few funds, outside of United Nation agen-
cies, are made available on a global basis. The alternative, 
however, of developing national or regional solutions and 
then attempting to join them up is likely to lead to even 
more difficulties, and costs, in the long term.
We believe the 10 principles outlined in this report 
are relevant globally, but we accept that some of the 
recommendations may not be completely applicable to 
other contexts (or countries) without adaptation. The 
recommendations were generated using, in the main, 
a non-commercial European perspective, with a focus 
on clinical trials. It will be important to try and explore 
further how differences in regulations or research systems 
in countries outside Europe could affect the applicability 
of these recommendations.
For example, in the USA, recent guidelines have indi-
cated that the sharing of de-identified IPD  from clin-
ical trials does not require separate consent from trial 
participants, assuming that the term ‘de-identified data’ 
means data that would not constitute identifiable private 
information in the hands of a third party. Under certain 
circumstances this ruling can also apply to data released 
with a code in place (ie, pseudonymous data).90 This is 
contrary to the position in Europe.
An additional difficulty is that the legislative and regu-
latory context in many places is rapidly changing. This 
is the case in Europe, with the introduction of the new 
General Data Protection and Clinical Trials Regulations, 
but also (for instance) in Japan, where the Personal 
Information Protection Act, Clinical Research Act and 
Next-Generation Medical Base Act were established in 
March and April 2017. These acts describe how to handle 
IPD for data sharing and deal with, among other things, 
informed consent regulations (K Takenouchi and D Naka-
tani, personal communication, 2017). We have to develop 
mechanisms to monitor and interpret the changing legis-
lative and regulatory frameworks, and design systems 
around them appropriately.
We believe that the international task force has 
constructed a comprehensive framework of policies and 
procedures for data sharing in clinical trials. The next 
steps will be to disseminate the principles and recommen-
dations in this framework, engaging different communi-
ties and countries, liaising with other major initiatives in 
the field at regional and global levels, and discuss how the 
various components of the data sharing infrastructure we 
need can be funded and implemented.
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